Publications by authors named "Jennifer Visich"

Claim this Profile
C
Cemiplimab in Japanese patients with advanced non-small cell lung cancer.
Yuki Sato, Yoko Tani, Hidenobu Ishii, Seigo Katakura, Masahide Oki, Jennifer E Visich

Jpn J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development.
John D Davis, Marçal Bravo Padros, Daniela J Conrado, Samit Ganguly, Xiaowen Guan, Jennifer Visich

Clin Pharmacol Ther· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancer.
Angelica L Quartino, Carina Hillenbach, Jing Li, Hanbin Li, Russell D Wada, Jennifer Visich

Cancer Chemother Pharmacol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration.
Yanan Zheng, Devin B Tesar, Lisa Benincosa, Herbert Birnböck, C Andrew Boswell, Jennifer Visich

MAbs· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD.
Robert L Avery, Alessandro A Castellarin, Nathan C Steinle, Dilsher S Dhoot, Dante Joseph Pieramici, Jennifer E Visich

Br J Ophthalmol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edema.
Yi Zhang, Zhenling Yao, Nitin Kaila, Peter Kuebler, Jennifer Visich

Ophthalmology· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.
Amit Garg, Angelica Quartino, Jing Li, Jin Jin, D Russell Wada, Jennifer Visich

Cancer Chemother Pharmacol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel.
Javier Cortés, Sandra M Swain, Iveta Kudaba, Maik Hauschild, Taral Patel, Jennifer Visich

Anticancer Drugs· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters.
Amit Garg, Jing Li, Emma Clark, Adam Knott, Timothy J Carrothers, Jennifer Visich

Cancer Chemother Pharmacol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis.
Paul J Rutgeerts, Richard N Fedorak, Daan W Hommes, Andreas Sturm, Daniel C Baumgart, Jennifer Visich

Gut· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy.
Rui Zhu, Yanan Zheng, Wendy S Putnam, Jennifer Visich, Mark D Eisner

AAPS J· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon.
Jing Li, Manish Gupta, Denise Jin, Yan Xin, Jennifer Visich

Cancer Chemother Pharmacol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia.
Jing Li, Jianguo Zhi, Michael Wenger, Nancy Valente, Anna Dmoszynska, Jennifer Visich

J Clin Pharmacol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of anti-BR3 monoclonal antibody in mice.
Anshu Marathe, Suhasini Iyer, Zhihua Julia Qiu, Jennifer Visich, Donald E Mager

Pharm Res· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept.
Michela Carbonatto, Ping Yu, Mauro Bertolino, Enrico Vigna, Stephanie Steidler, Jennifer Visich

Toxicol Sci· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody.
Wendy S Putnam, Jing Li, Jonas Haggstrom, Chee Ng, Saloumeh Kadkhodayan-Fischer, Jennifer Visich

AAPS J· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis.
Ivan Nestorov, Alain Munafo, Orestis Papasouliotis, Jennifer Visich

J Clin Pharmacol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting immune complex-mediated hypersensitivity with recombinant soluble human FcgammaRIA (CD64A).
Jeff L Ellsworth, Mark Maurer, Brandon Harder, Nels Hamacher, Megan Lantry, Jennifer Visich

J Immunol· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers.
Alain Munafo, Anthony Priestley, Ivan Nestorov, Jennifer Visich, Mark Rogge

Eur J Clin Pharmacol· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical safety of recombinant human thrombin.
Jane K Heffernan, Rafael A Ponce, Linda A Zuckerman, John P Volpone, Jennifer Visich

Regul Toxicol Pharmacol· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency.
Amy E Lovejoy, Tom C Reynolds, Jennifer E Visich, Michael D Butine, Guy Young

Blood· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pharmacokinetics of recombinant factor XIII in healthy volunteers: a randomized, placebo-controlled, double-blind, multi-dose study.
Jennifer E Visich, Linda A Zuckerman, Michael D Butine, Kulasiri A Gunewardena, Richard Wild

Thromb Haemost· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of recombinant factor XIII in cynomolgus monkeys.
Michael G Dodds, Jennifer E Visich, Paolo Vicini

AAPS J· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical safety and pharmacokinetics of recombinant human factor XIII.
Rafael A Ponce, Jennifer E Visich, Jane K Heffernan, Kenneth B Lewis, Susan Pederson

Toxicol Pathol· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis